Re-appointment of Cost Auditors for the F.Y. 2026-27

Ceo ResignedManagement Changes View source PDF Explain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.4%Reaction day

₹790.00

prior close

₹730.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-10.1% vs market

Pharmaceuticals peers, median of 162sector+0.0%-9.4% vs sector

On the reaction day the stock moved 10.1 pts less than Nifty Microcap 250 and 9.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.9

15m

-2.3

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.4+0.7-10.1+0.0-9.4

Next day

-10.5+0.9-11.4+0.5-11.0

-8.6+0.6-9.2+0.0-8.6

-10.1-0.8-9.3-0.6-9.5

-9.2-0.4-8.9-0.1-9.2

-10.4+0.2-10.6+1.0-11.3

-10.6+1.4-12.1+0.8-11.5

15d

-8.8+4.2-13.0+1.1-9.9

-8.3+6.3-14.6+2.6-11.0

-11.2+11.3-22.5+6.8-18.0

+1.7+14.0-12.3+9.2-7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Albert David Ltd held its Board Meeting on May 12, 2026, announcing several key decisions. The company appointed Mr. Amit Mahla as new CEO (effective May 12, 2026), replacing Mr. Umesh Manohar Kunte who resigned as Managing Director & CEO in December 2025. For FY 2025-26, the company reported a net loss of Rs. 149.47 Lakhs compared to a profit of Rs. 1,720.08 Lakhs in FY 2024-25 — a significant decline. Revenue from operations stood at Rs. 33,359.81 Lakhs. The Board recommended a final dividend of Rs. 5 per share (50% on Rs. 10 face value), subject to shareholder approval at the 87th AGM on August 6, 2026. Cost Auditors M/s. S. Gupta & Co. and Internal Auditors M/s. PricewaterhouseCoopers Services LLP were reappointed for FY 2026-27. Statutory auditors issued an unmodified opinion.

Likely market impact

The company swung from profit to loss in FY 2026, raising concerns about operational performance. The appointment of a new CEO from pharma giants like Cipla and Sun Pharma could bring strategic turnaround. Positive dividend declaration may provide some support to shareholders despite the loss.